secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001193125-23-132621
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion receives FDA clearance for IND of BMF-500 in relapsed/refractory acute leukemia
--------------------------------------------------------------------------------

- FDA cleared IND for BMF-500, a novel covalent FLT3 inhibitor, to begin Phase I trial COVALENT-103 in adult patients with relapsed or refractory acute leukemia.
- BMF-500 is the second investigational compound from Biomea's FUSION System to enter the clinic.
- Preclinical data: BMF-500 showed ~20-fold greater potency than gilteritinib and >50-fold greater than reversible menin/MLL inhibitors in AML cell lines.
- Combination of BMF-500 and BMF-219 showed greater than additive cell killing in acute leukemia cell lines and patient samples.
- BMF-500 designed for high target selectivity with minimal off-target liabilities; potential for combinations with standard of care or BMF-219.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523132621/0001193125-23-132621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523132621/d851586d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-132621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer